major
chikungunya
viru
chikv
epidem
reach
america
past
year
million
peopl
infect
light
current
epidem
million
peopl
north
south
america
risk
effort
rapidli
develop
effect
vaccin
increas
focu
chikv
vaccin
use
viralvector
technolog
group
vaccin
candid
share
abil
potent
induc
humor
cellular
immun
respons
use
highli
attenu
safe
vaccin
backbon
far
welldescrib
vector
modifi
vaccinia
viru
ankara
complex
adenoviru
vesicular
stomat
viru
alphavirusbas
chimera
measl
vaccin
schwarz
strain
mvschw
describ
potenti
vaccin
summar
recent
data
experiment
vaccin
focu
preclin
clinic
activ
mvschwbase
candid
first
chikvvector
vaccin
complet
clinic
trial
chikungunya
viru
chikv
positivestrand
rna
alphaviru
transmit
aed
mosquito
infect
case
symptomat
acut
febril
ill
patient
viru
caus
debilit
arthriti
last
month
year
consequ
chikv
epidem
present
major
public
health
threat
substanti
morbid
suffer
loss
econom
product
especi
lowincom
countri
past
decad
number
research
effort
launch
develop
chikv
vaccin
howev
owe
low
incid
chikv
infect
la
epidem
research
activ
slow
first
case
chikv
infect
report
decemb
caribbean
island
martiniqu
million
peopl
infect
year
substanti
fuel
develop
effort
chikv
vaccin
potenti
chikv
vaccin
induc
protect
immun
respons
immun
enabl
effect
immun
program
chikvendem
area
well
travel
addit
vaccin
easili
manufactur
low
cost
lowincom
countri
disproportion
affect
diseas
current
correl
protect
chikv
establish
howev
gener
opinion
level
chikv
neutral
antibodi
correl
protect
diseas
role
cell
protect
diseas
still
investig
chikvspecif
tcell
activ
occur
earli
infect
like
play
role
control
viral
infect
prior
antibodi
respons
chikv
circul
genotyp
asian
east
centralsouth
african
ecsa
west
african
strain
close
relat
amino
acid
similar
high
similar
allow
potenti
protect
heterolog
strain
vaccin
singl
genotyp
thu
crossprotect
chikv
vaccin
produc
use
singlegeneticlineag
vaccin
antigen
current
vaccin
develop
includ
contain
attenu
chikv
strain
recombin
protein
vaccin
subunit
viruslik
particl
vlp
formalininactiv
vaccin
dna
vaccin
viralvector
vaccin
today
numer
liveattenu
vaccin
approv
use
decad
excel
efficaci
safeti
class
vaccin
well
establish
allow
develop
vector
system
deliv
antigen
origin
pathogen
use
viral
vector
potent
tool
gene
therapi
vaccin
develop
abil
induc
potent
humor
cellular
immun
respons
heterolog
antigen
express
deliv
relev
tissu
gener
effici
pathogenspecif
host
respons
addit
immunogen
enhanc
intrins
vector
motif
stimul
innat
immun
pathway
thu
use
expens
mostli
reactiv
adjuv
omit
viral
vector
use
hostcel
proteinprocess
pathway
lead
antigen
present
via
major
histocompat
complex
class
consequ
cytotox
tcell
stimul
addit
viral
vector
produc
high
quantiti
rel
low
cost
allow
use
system
lowincom
countri
despit
mani
advantag
potenti
viralvector
vaccin
preexist
antivector
immun
major
obstacl
develop
pathway
vectorspecif
antibodi
may
imped
induct
immun
respons
heterolog
express
protein
reduc
dose
time
exposur
vaccin
antigen
strategi
overcom
possibl
problem
includ
increas
vector
dose
use
vector
deriv
nonhuman
pathogen
eg
chimpanze
adenoviru
ad
vesicular
stomat
viru
vsv
use
heterolog
primeboost
approach
current
strategi
develop
chikv
vaccin
base
viralvector
technolog
summar
tabl
live
recombin
measl
vaccin
vector
technolog
mani
advantag
technolog
base
measl
viru
mv
vaccin
schwarz
strain
mvschw
liveattenu
negativestrand
rna
viru
one
safest
effect
human
vaccin
measl
vaccin
wide
use
past
year
prevent
mv
infect
dramat
reduc
childhood
mortal
measl
sinc
introduct
vaccin
safe
induc
lifelong
protect
immun
singl
immun
entir
viru
life
cycl
limit
cytoplasm
prevent
insert
foreign
gene
host
genom
addit
vaccin
dose
produc
larg
scale
distribut
low
cost
convent
recombin
measl
vaccin
strain
extens
studi
past
decad
tool
cancer
therapi
owe
intrins
abil
target
destroy
cancer
cell
number
clinic
trial
conduct
mani
case
use
high
dose
log
higher
compar
mv
vaccin
demonstr
safeti
viral
vector
system
mv
vector
thu
appear
appropri
develop
safe
costeffect
chikv
vaccin
use
case
chikv
emerg
revers
genet
system
rescu
negativestrand
mv
genom
establish
singl
multipl
heterolog
gene
express
stabli
recombin
vector
total
size
approxim
kb
tangi
et
al
pasteur
institut
pari
introduc
liveattenu
mvschw
vector
express
heterolog
viral
antigen
complementari
dna
cdna
plasmid
gener
contain
fulllength
infecti
antigenom
mvschw
addit
atu
site
insert
differ
measl
viru
genom
region
allow
introduct
heterolog
gene
control
cisact
promot
element
model
present
nucleocapsidphosphoprotein
boundari
region
allow
transcript
stop
upstream
gene
well
autonom
transcript
cap
polyadenyl
transgen
date
mv
schwarz
vector
proven
effect
tool
gener
recombin
mv
clone
express
heterolog
viral
antigen
includ
west
nile
viru
dengu
viru
human
immunodefici
viru
sar
coronaviru
recombin
vaccin
induc
strong
vaccin
candid
induc
robust
protect
humor
cellular
immun
respons
tg
ifnar
mice
immun
one
hundr
percent
vaccin
anim
protect
lethal
challeng
singl
immun
even
presenc
measl
preexist
immun
passiv
transfer
mvchik
preimmun
sera
naiv
mice
confer
protect
lethal
challeng
base
result
addit
nonclin
anim
safeti
data
themi
bioscienc
unpublish
data
phase
clinic
trial
conduct
austria
medic
univers
vienna
first
clinic
trial
design
test
safeti
toler
immunogen
recombin
vaccin
presenc
preexist
antimv
immun
eudract
total
healthi
volunt
age
year
mean
age
year
white
includ
random
observerand
subjectblind
doseescal
trial
thirtysix
subject
receiv
one
mvchik
dose
tissu
cultur
infect
dose
per
dose
subject
receiv
control
vaccin
priorix
measlesmumpsrubella
vaccin
contain
parenter
mvschw
strain
subject
blockrandom
receiv
vaccin
booster
dose
month
first
immun
allow
assess
shortterm
booster
well
antibodi
persist
month
singl
immun
induc
chikv
neutral
antibodi
geometr
mean
titer
gmt
dose
group
per
protocol
popul
n
shown
plaqu
reduct
neutral
test
prnt
gmt
first
immun
reach
second
immun
gmt
reach
lowdos
group
highdos
group
seroconvers
rate
first
immun
boost
treatment
cohort
second
immun
either
month
first
dose
observ
signific
differ
antichikv
prnt
gmt
group
lowor
hightit
basal
antimv
antibodi
show
preexist
measl
immun
impair
respons
transgen
function
mv
vector
preimmun
popul
fundament
develop
vector
technolog
although
reason
capac
investig
might
due
replic
capac
live
vector
capac
taken
antigenpres
cell
without
depend
specif
receptor
overal
mvchik
safeti
toler
profil
accept
vaccin
induc
seriou
advers
event
frequent
observ
solicit
advers
event
includ
headach
inject
site
pain
influenzalik
ill
transient
musculoskelet
pain
report
subject
first
visit
overal
particip
experienc
local
pain
erythema
headach
pyrexia
number
solicit
local
vaccin
reaction
increas
dose
howev
consid
relat
high
inocul
volum
vaccin
saltbuff
diluent
rather
activ
ingredi
furthermor
clinic
relev
abnorm
safeti
laboratori
paramet
urinalysi
result
observ
mechan
action
mvchik
vaccin
current
investig
howev
abil
recombin
vaccin
potenti
produc
vlp
result
format
highli
immunogen
epitop
like
main
immunolog
determin
mvchik
function
support
anoth
project
involv
nonrepl
chikv
vlp
vaccin
chang
et
al
demonstr
vaccin
potenc
phase
doseescal
openlabel
clinic
trial
adult
volunt
even
absenc
adjuv
vaccin
induc
potent
neutral
antibodi
respons
booster
dose
vaccin
recombin
approach
review
issu
j
ledgerwood
et
al
mvchik
vaccin
earli
stage
develop
therefor
inform
need
determin
import
detail
target
popul
includ
pediatr
popul
subject
recent
measlesvaccin
need
clinic
evalu
subsequ
trial
mvchik
vaccin
enter
phase
clinic
trial
confirm
dose
schedul
clinic
develop
central
aspect
trial
determin
immunogen
reactogen
vector
larger
mv
preimmun
popul
fundament
asset
chikv
vaccin
mvschw
platform
technolog
alphavirus
positivestrand
rna
virus
togavirida
famili
sever
type
alphaviru
vector
system
engin
replicationdefici
vector
consist
nake
rna
recombin
singleround
infecti
alphaviru
particl
layer
dna
vector
code
alphaviru
replicon
particl
vector
system
take
advantag
extrem
effici
alphaviru
rna
replic
machineri
make
rna
copi
rna
molecul
chikv
vaccin
vector
play
special
role
chikv
also
member
genu
alphaviru
experiment
alphavirusbas
chikv
vaccin
replicationcompet
chimer
virus
construct
compos
chikv
structur
gene
combin
less
pathogen
alphavir
nonstructur
gene
previou
studi
neurotrop
alphavirus
show
combin
replic
enzym
one
alphaviru
structur
protein
anoth
result
highli
attenu
phenotyp
smallanim
model
insert
genet
element
alter
viru
life
cycl
increas
safeti
vector
system
nonstructur
protein
gene
includ
subgenom
promot
cisact
promot
element
either
venezuelan
equin
enceph
viru
attenu
vaccin
strain
eastern
equin
enceph
sindbi
viru
combin
chikv
structur
gene
deriv
la
strain
chimera
induc
robust
neutral
antibodi
titer
vaccin
nation
institut
health
swiss
mice
even
high
dose
anim
show
sign
neurolog
diseas
demonstr
preclin
safeti
vaccin
candid
natur
attenu
eastern
equin
enceph
backbon
immunogen
sindbi
viru
backbon
increas
safeti
potenc
vaccin
candid
mechan
replic
viru
host
interact
investig
promot
regul
chikv
structur
gene
replac
encephalomyocard
virusderiv
intern
ribosom
entri
site
ire
immunocompet
mice
immunocompromis
type
interferondefici
mice
singl
vaccin
induc
robust
neutral
titer
protect
mice
chikv
viremia
death
chikv
challeng
import
featur
regard
safeti
inhibit
viru
replic
mosquito
cell
ire
make
mosquito
transmiss
novel
vector
imposs
anoth
approach
attenu
chikv
gener
introduct
ire
chikv
genom
result
effect
safe
vaccin
candid
detail
review
elsewher
issu
weaver
et
al
ad
vector
base
famili
doublestrand
dna
virus
typic
caus
respiratori
gastrointestin
infect
human
vector
well
describ
studi
gene
therapi
vaccin
clinic
trial
larg
safeti
databas
yield
trial
suggest
vaccin
gene
therapi
vector
safe
well
toler
ad
vector
easili
produc
high
titer
vaccin
formul
maintain
requir
stabil
commerci
use
viral
vector
preexist
immun
major
concern
develop
adbas
vaccin
seropreval
us
popul
high
howev
preexist
immun
might
overcom
increas
dose
construct
recombin
ad
vectorbas
chikv
vaccin
character
mice
describ
wang
et
al
entir
chikv
orf
deriv
la
isol
encod
structur
gene
insert
nonrepl
complex
ad
vaccin
cadvax
vector
cadvax
base
backbon
lack
transgen
control
immedi
earli
human
cytomegaloviru
promot
bovin
growth
hormon
polyadenyl
signal
bghpa
sequenc
mice
immun
twice
via
intraperiton
rout
high
level
chikvspecif
antibodi
induc
singl
vaccin
neutral
antibodi
titer
homolog
ecsa
strain
heterolog
asian
strain
reach
similar
high
level
addit
vaccin
anim
challeng
rear
feet
homolog
heterolog
chikv
strain
induc
arthrit
diseas
manifest
selflimit
perimetatars
swell
singl
immun
cadvaxchik
protect
chikv
viremia
joint
swell
togeth
data
present
show
potent
experiment
vaccin
evalu
use
human
mva
viru
deriv
turkish
smallpox
vaccin
strain
chorioallantoi
vaccinia
viru
ankara
passag
chicken
embryon
fibroblast
cell
newli
gener
strain
lost
nearli
kb
viral
genom
genom
locat
mainli
impact
host
respons
infect
mva
particl
initi
viral
life
cycl
unabl
product
grow
gener
infecti
viral
particl
human
cell
poxviru
vector
effici
induc
heterolog
antigenspecif
tcell
antibodi
respons
human
famili
vaccin
vector
extens
use
human
past
decad
without
rais
safeti
concern
recent
independ
studi
describ
mvabas
chikv
vaccin
candid
preclin
develop
martina
et
al
describ
gener
character
recombin
mva
virus
express
chikv
insert
deriv
strain
entir
envelop
protein
cassett
immun
immunocompromis
mice
recombin
virus
induc
neutral
antibodi
homolog
chikv
strain
titer
elicit
low
prnt
titer
induc
full
envelop
gene
significantli
higher
prnt
interestingli
fulli
protect
chikvsuscept
mice
lethal
challeng
chikv
strain
similar
find
report
anoth
laboratori
recombin
mva
construct
express
select
antigen
singl
immunogen
driven
recent
studi
describ
major
neutral
antigen
primari
infect
coexpress
peptid
facilit
correct
fold
protein
total
wildtyp
balbc
mice
immun
vector
protect
viremia
addit
mice
lack
type
ifn
receptor
protect
viremia
footpad
swell
mortal
despit
recent
data
suggest
would
contain
main
neutral
epitop
sera
mice
immun
low
neutral
antibodi
titer
addit
passiv
transfer
sera
immun
mice
protect
lethal
challeng
mice
howev
cell
critic
protect
mice
challeng
togeth
independ
studi
clearli
demonstr
neutral
antibodi
confer
protect
chikv
infect
howev
role
cellular
respons
rule
garciaarriaza
et
al
describ
anoth
mva
vaccin
candid
chikv
insert
deriv
indian
ocean
strain
vaccin
strain
induc
high
titer
neutral
antibodi
strong
cellular
tcell
respons
mvachik
vaccin
protect
mice
challeng
footpadswel
model
mvabas
chikv
candid
describ
immunogen
protect
chikv
challeng
differ
mous
model
howev
express
full
structur
gene
cassett
induc
potent
neutral
cellular
immun
respons
balanc
respons
certainli
effect
approach
vsv
negativestrand
rna
viru
rhabdovirida
famili
viru
backbon
use
experiment
vaccin
vector
sever
viral
bacteri
pathogen
recent
recombin
vsv
vaccin
express
zair
ebola
viru
glycoprotein
g
test
phase
trial
involv
healthi
volunt
vaccin
reactogen
human
effect
dose
accept
immunogenicitytoler
ratio
yet
determin
vsv
vector
lack
glycoprotein
g
use
express
heterolog
viral
antigen
produc
chimer
virus
experiment
vaccin
design
express
chikv
structur
gene
vsv
backbon
recombin
virus
incorpor
chikv
protein
surfac
allow
propag
cell
cultur
mice
immun
either
vsvchik
induc
high
titer
neutral
antibodi
vaccin
induc
superior
antibodi
respons
vaccin
anim
protect
challeng
footpad
swell
mous
model
anim
show
reduc
viremia
level
addit
vsvchik
construct
induc
chikv
chikv
tcell
respons
singl
immun
data
demonstr
potent
effect
vector
system
express
chikv
antigen
major
advantag
system
lack
antivector
antibodi
due
lack
g
surfac
protein
howev
reactogen
system
human
observ
detail
largescal
clinic
trial
launch
develop
effect
vaccin
prevent
chikv
infect
great
interest
owe
presenc
larg
chikvnaiv
popul
america
strategi
describ
outlin
vaccin
technolog
gener
nextgener
vaccin
common
strategi
present
use
replic
virus
vaccin
carrier
experiment
vaccin
potent
safe
anim
model
vaccin
safeti
potenc
yet
determin
background
antivector
immun
compar
differ
chikv
antigen
test
data
suggest
full
envelop
gene
cassett
entir
orf
express
structur
gene
allow
vlp
format
yield
mostpot
mostprotect
vaccin
candid
import
aspect
address
vector
approach
role
preexist
antivector
immun
one
vector
candid
mvschw
vaccin
enter
phase
clinic
trial
soon
give
valuabl
data
potenc
safeti
system
larger
popul
financi
support
work
support
ventur
captit
ffg
research
promot
agenc
potenti
conflict
interest
k
r
employe
themi
bioscienc
pharmaceut
compani
engag
develop
commerci
mvschw
base
mvchik
vaccin
f
employe
centr
nation
de
la
recherch
scientifiqu
inventor
mvschw
technolog
receiv
person
fee
themi
bioscienc
vaccin
develop
author
submit
icmj
form
disclosur
potenti
conflict
interest
conflict
editor
consid
relev
content
manuscript
disclos
